Clinical Trial: Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801898) titled 'Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer' on Aug. 26.

Brief Summary: The goal of this investigator-initiated, open-label, phase II clinical trial is to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, Ki67 > 20% invasive breast cancer.

The main questions it aims to answer are:

What is the objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 criteria at the compl...